Global Entrectinib Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Entrectinib Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.
Entrectinib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Entrectinib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Anaplastic Lymphoma and C-ros Oncogene are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Entrectinib industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Entrectinib key manufacturers include BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. BOCSCI, APExBIO Technology, Cayman Chemical are top 3 players and held % sales share in total in 2022.
Entrectinib can be divided into 0.99 and 0.98, etc. 0.99 is the mainstream product in the market, accounting for % sales share globally in 2022.
Entrectinib is widely used in various fields, such as Anaplastic Lymphoma and C-ros Oncogene, etc. Anaplastic Lymphoma provides greatest supports to the Entrectinib industry development. In 2022, global % sales of Entrectinib went into Anaplastic Lymphoma filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Entrectinib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
BOCSCI
APExBIO Technology
Cayman Chemical
ChemScence
Crysdot
Medical Isotopes
TargetMol Chemicals
Toronto Research Chemicals
Beijing Jingming Biotechnology
Cool Pharm
Shanghai Lollane Biological Technology
Shanghai Macklin Biochemical
Shanghai Muse Health Tech
ATK Chemical
Shanghai Send Pharmaceutical Technology
Shanghai Yuanye Bio-Technology
Wuhan Sun-Shine Bio-Technology
Segment by Type
0.99
0.98
Anaplastic Lymphoma
C-ros Oncogene
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Entrectinib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Entrectinib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Entrectinib industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Entrectinib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Entrectinib introduction, etc. Entrectinib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Entrectinib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Entrectinib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Entrectinib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Anaplastic Lymphoma and C-ros Oncogene are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Entrectinib industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Entrectinib key manufacturers include BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. BOCSCI, APExBIO Technology, Cayman Chemical are top 3 players and held % sales share in total in 2022.
Entrectinib can be divided into 0.99 and 0.98, etc. 0.99 is the mainstream product in the market, accounting for % sales share globally in 2022.
Entrectinib is widely used in various fields, such as Anaplastic Lymphoma and C-ros Oncogene, etc. Anaplastic Lymphoma provides greatest supports to the Entrectinib industry development. In 2022, global % sales of Entrectinib went into Anaplastic Lymphoma filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Entrectinib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
BOCSCI
APExBIO Technology
Cayman Chemical
ChemScence
Crysdot
Medical Isotopes
TargetMol Chemicals
Toronto Research Chemicals
Beijing Jingming Biotechnology
Cool Pharm
Shanghai Lollane Biological Technology
Shanghai Macklin Biochemical
Shanghai Muse Health Tech
ATK Chemical
Shanghai Send Pharmaceutical Technology
Shanghai Yuanye Bio-Technology
Wuhan Sun-Shine Bio-Technology
Segment by Type
0.99
0.98
Segment by Application
Anaplastic Lymphoma
C-ros Oncogene
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Entrectinib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Entrectinib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Entrectinib industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Entrectinib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Entrectinib introduction, etc. Entrectinib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Entrectinib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.